To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients (Ral'inNONB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01162538|
Recruitment Status : Unknown
Verified May 2010 by Centre Hospitalier Intercommunal Robert Ballanger.
Recruitment status was: Not yet recruiting
First Posted : July 14, 2010
Last Update Posted : July 14, 2010
|Condition or disease|
|Evaluated Non B Subtype Naive Patients|
The population VIH1 not B is not unimportant in our region of the Seine St Denis, a tendency which seems to be in increase (47 % in 2006, 67 % in 2007).
Most of the studies evaluating the clinical, immunologic and virologic response to the ARV according to the viral subcategories are corresponding and show comparable results for patients infected by HIV 1 of subcategory B or non B. In spite of these reassuring results, it is necessary to evaluate the efficiency of a new ARV all the more a new class. It seems also necessary to observe attentively the profiles of resistance which will be selected at the carrier patient's of virus of subcategories not - B in failure of treatment. It will allow to determine if, because of the important polymorphisms of the viruses not - B, the evolution towards the resistance will be made differently.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||The Main Objective of This Study is to Evaluate the Virologic Effectiveness at M6 of Regimen Containing Raltegravir in Treatment Naive HIV Subtype Non B or B Infected Subjects|
|Study Start Date :||September 2010|
|Estimated Primary Completion Date :||March 2011|
|Estimated Study Completion Date :||March 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01162538
|Aulnay sous Bois, France, 93602|
|Contact: Delassus Jean-Luc, MD 1 49 36 72 81 ext +33 email@example.com|
|Principal Investigator:||Delassus Jean-Luc, MD||Réseau Aulnay 93|